Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06112743 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study acronym: MEMENTO
StatusActive, Not Recruiting
PhasePhase 4
Started2024-01-24
View on ClinicalTrials.gov ↗

Amendment history

2026-09-17
Completion moved earlier: 2027-07-10 → 2027-06-10
2026-08-04
Study Status, IPDSharing v26
Completion pushed: 2026-07-09 → 2027-07-10
Primary completion dateestimated 2026-07-09→confirmed 2026-07-16
2025-09-19
Study Status v25
Primary completion date2026-09-30→2026-07-09
Completion date2026-09-30→2026-07-09
2025-08-28
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v24
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 85→confirmed 63
Study sites89→23
2025-06-30
Study Status, Contacts/Locations v23
Primary completion date2026-07-31→2026-09-30
Completion date2026-07-31→2026-09-30
Study sites89 entries, revised
Cedars Sinai Medical Center - 1207127 San Vicente Blvd Leeds General Infirmary - PPDS
Show 22 earlier versions
2025-06-03
Study Status, Contacts/Locations v22
Study sites89 entries, revised
LocalInstituto InstitutionCardiovascular de Buenos Aires - 0075 Local InstitutionICBA - 0079Blanco Encalada 1543 Hospital Universitario Austral
2025-05-14
Study Status, Contacts/Locations v21
Study sites89 entries, revised
LocalInstitut InstitutionUniversitaire de Cardiologie et de Pneumologie de Quebec - 0068Université Laval
2025-04-14
Study Status, Contacts/Locations v20
Study sites89 entries, revised
LocalCedars InstitutionSinai Medical Center - 00871207 San Vicente Blvd LocalSanatorio InstitutionAllende S.A.-Pedro 0077Simón Laplace 5749 LocalHospital InstitutionPrivado -de 0074Rosario
2025-03-27
Study Status, Contacts/Locations v19
Study sites89 entries, revised
LocalInstitut Institutionde -Cardiologie 0001de Montreal
2025-03-06
Study Status, Contacts/Locations v18
Study sites89 entries, revised
LocalMassachusetts InstitutionGeneral Hospital Fundación Favaloro - 0093 LocalAvenida InstitutionBelgrano - 00761746
2025-02-20
Study Status, Contacts/Locations, References v17
Study sites89 entries, revised
LocalHospital InstitutionItaliano -de 0080Buenos Aires
2025-01-13
Study Status, Contacts/Locations v16
Study sites89 entries, revised
LocalUniversity InstitutionHospitals Cleveland Medical Center - 009011100 Euclid Ave
2024-12-19
Study Status, Contacts/Locations, References v15
Study sites89 entries, revised
LocalThe InstitutionAlfred -Hospital Luzerner 0005Kantonsspital (LUKS) LocalIstituto Institution - 0061 Local Institution - 0058 Cardiocentro Ticino Hôpitaux Universitaires de Genève
2024-11-06
Study Status, Contacts/Locations v14
Study sites89 entries, revised
LocalRoyal InstitutionPrince -Alfred 0015Hospital
2024-10-30
Study Status, Contacts/Locations v13
Study sites89 entries, revised
LocalAllegheny InstitutionGeneral - 0086Hospital LocalCardiocentro Institution - 0029Ticino
2024-10-18
Study Status, Contacts/Locations v12
Study sites89 entries, revised
LocalLeeds InstitutionGeneral - 0025Infirmary
2024-10-15
Study Status, Contacts/Locations v11
Study sites89 entries, revised
IntermountainLocal MedicalInstitution Center- 0035 LocalUniversitätsspital Institution - 0024Zürich
2024-10-04
Study Status, Contacts/Locations v10
Study sites89 entries, revised
LocalIntermountain InstitutionMedical - 0035Center
2024-09-18
Active, Not Recruiting→Recruiting Study Status, Contacts/Locations, References v9
Trial statusActive, Not Recruiting→Recruiting
Primary completion date2025-07-31→2026-07-31
Completion date2026-12-31→2026-07-31
Study sites12→89
2024-07-29
Recruiting→Active, Not Recruiting Study Identification, Study Status, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v8
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-10-31→2025-07-31
Completion date2026-10-30→2026-12-31
Enrollment target100→85
Study sites75→12
Study arms2→1
InterventionsMavacamten (Drug), Placebo (Other)→Mavacamten (Drug)
Eligibility criteria-1 characters
Inclusion Criteria: Diagnosed with obstructive hypertrophic cardiomyopathy (oHC [...] tion and European Society of Cardiology guidelines as below:. Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mm HgmmHg and ≥ 50 mm HgmmHg after Valsalva or after exercise. Left ventricular ejection fraction (LVEF) ≥ 55% at rest. New York Heart Association (NYHA) functional class II or III symptoms. Exclusion Criteria: A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM. Documented obstructive coronary artery disease or history of myocardial infarction. A history of resusci [...] [...]
Secondary endpoints18 to 17 entries
Change from baseline in maximum left atrial volume index (LAVI) at Week 48 Incidence of resuscitatedHF cardiacevents arrestwith systolic dysfunction Incidence of treatment emergent laboratory abnormalities Incidence of adverse eventscardiovascular (AEsCV) mortality Incidence of serious adverse events (SAEs) Incidence of AEsTEAEs leading to discontinuation from study intervention TEAEs leading to laboratory abnormalities
Primary endpoints1 entry, revised
Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48
2024-05-10
Study Status, Contacts/Locations v7
Study sites73→75
2024-03-28
Study Status, Contacts/Locations v6
Study sites40→73
2024-02-26
Study Status, Contacts/Locations v5
Completion date2026-11-20→2026-10-30
Study sites32→40
2024-02-01
Study Status, Contacts/Locations v4
Start dateestimated 2024-01-31→confirmed 2024-01-24
Study sites28→32
2024-01-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations, References v3
Trial statusNot Yet Recruiting→Recruiting
Start date2023-12-30→2024-01-31
Study sites27→28
2023-12-15
Study Status, Contacts/Locations v2
Start date2023-11-20→2023-12-30
Study sites16→27
2023-11-13
Study Status, Contacts/Locations v1
Study sites10→16
2023-10-27
Original filing
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].
Trial Details
NCT Number NCT06112743
Lead Sponsor Bristol-Myers Squibb
Conditions Cardiomyopathy, Hypertrophic
Enrollment 63 participants
Start Date 2024-01-24
Primary Completion 2026-07-16 (estimated)
Study Completion 2027-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-09-16